Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 12:10 p.m. ET. The event aims to showcase Entrada's focus on creating Endosomal Escape Vehicle (EEV™) therapeutics to tackle previously unaddressed intracellular targets. A live webcast of the chat will be available on the company's website, followed by a 90-day replay. Entrada is developing EEV therapeutics to enhance treatment for various diseases, including Duchenne muscular dystrophy.

BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 4^th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 12:10 p.m. Eastern Time.

A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com, or by clicking here. A replay will be available on the Entrada website for 90 days following the event.

About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).

Entrada/Investor Contact
Karla MacDonald
VP, Corporate Communications
kmacdonald@entradatx.com

Media Contact
Aulani Capuchin
Real Chemistry
acapuchin@realchemistry.com
(559) 355-2673

FAQ

What is the date and time of the Entrada Therapeutics event?

The Entrada Therapeutics event is scheduled for December 2, 2021, at 12:10 p.m. Eastern Time.

Who will represent Entrada Therapeutics at the conference?

Dipal Doshi, the President and CEO of Entrada Therapeutics, will represent the company at the conference.

Where can I watch the Entrada Therapeutics fireside chat?

The fireside chat can be watched live on the Investor Relations section of Entrada Therapeutics' website.

What is the focus of Entrada Therapeutics?

Entrada Therapeutics focuses on developing Endosomal Escape Vehicle (EEV™) therapeutics to target intracellular diseases.

How long will the replay of the Entrada Therapeutics event be available?

The replay of the Entrada Therapeutics event will be available for 90 days following the event.